Title of Invention	ANTHRANILIC ACID AMIDES OF FORMULA I
Abstract	ABSTRACT 1696/CHENP/2003 The present invention relates to anthranilic acid amides, to a method for the production thereof, to their use as a medicament, and to pharmaceutical preparations containing these anthranilic acid amides. The anthranilic acid amides consists of compounds of formula (I) in which R(l) to {R7) have the meanings as cited in the claims, act upon the Kvl.5 potassium charmel, and inhibit a potassium described as an "ultra-rapidly activating delayed rectifier" in the human cardiac atrium. The compounds are therefore especially suited as novel antiarrhythmic active substances, particularly for treating and preventing atrial arrhythmias, e.g. atrial fibrillation AF or atrial flutter.

Title of Invention

ANTHRANILIC ACID AMIDES OF FORMULA I

Abstract

ABSTRACT 1696/CHENP/2003 The present invention relates to anthranilic acid amides, to a method for the production thereof, to their use as a medicament, and to pharmaceutical preparations containing these anthranilic acid amides. The anthranilic acid amides consists of compounds of formula (I) in which R(l) to {R7) have the meanings as cited in the claims, act upon the Kvl.5 potassium charmel, and inhibit a potassium described as an "ultra-rapidly activating delayed rectifier" in the human cardiac atrium. The compounds are therefore especially suited as novel antiarrhythmic active substances, particularly for treating and preventing atrial arrhythmias, e.g. atrial fibrillation AF or atrial flutter.

Full Text	ANTHRANILAMIDES. PROCESS FOR THEIR PREPARATION, THEIR USE AS ANTIARRHYTHMICS, AND PHARMACEUTICAL PREPARATIONS THEREOF The invention relates to compounds of the formula The compounds of the invention of the formula I have not previously been disclosed. They act on the so-called Kv1.5 potassium channel and Inhibit a potassium current, which is referred to as ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore very particularly suitable as novel antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, e.g. atrial fibrillation (AF) or atrial flutter. Atrial fibrillation (AF) and atrial flutter are the commonest persistent cardiac arrhythmias. The occurrence increases with increasing age and frequently leads to fatal sequelae such as, for example, stroke. It affects about 1 million Americans each year and leads to more than 80 000 strokes annually in the USA. The class I and til antiarrhythmics in use at present reduce the rate of recurrence of AF but are used to only a limited extent because of their potential proarrhythmic side effects. There is thus a great medical need to develop better medicaments tor the treatment of atrial arrhythmias (S. Nattel, Am. Heart J. 130,1995, 1094 -1106; "Newer developments in the management of atrial fibrillation"). It has been shown that most supraventricular arrhythmias are subject to so-called reentry waves. Such reentries occur when the cardiac tissue has a slow conductivity and, at the same time, very short refractory periods. Increasing the myocardial refractory period by prolonging the action potential is an acknowledged mechanism for terminating arrhythmias and preventing development thereof {T. J. Colatsky et al., Drug Dev. Res. 19, 1990,129 -140; "Potassium channels as targets for antiarrhythmic drug action"). The length of the action potential is essentially determined by the extent of repolarizing K+ currents which flow out of the cells through various K+ channels. Particularly great importance is ascribed in this connection to a so-called delayed rectifier 11 which consists of 3 different components: IKf, IKs and IKur- Most of the known class III antiarrhythmics (e.g. dofetilide, E4031 and d-sotalol) block predominantly or exclusively the rapidly activating potassium channel IK1, which can be detected both in cells o1 the human ventricle and in the atrium. However, it has emerged that these compounds have an increased proarrhythmic risk at heart rates which are low or normal, and arrhythmias referred to as torsades de pointes have been observed in particular (D. M. Roden, Am. J. Cardiol. 72, 1993, 44B - 49B; "Current status of class III antiarrhythmic drug therapy"). Besides this high risk, which is fatal in some cases, when the rate is low, the activity of the iKr blockers has been found to decline under the conditions of tachycardia, which Is just where the effect is required ("negative use-dependence"). Whereas some of the disadvantages can possibly be overcome by blockers of the slowly activating component (IKs). their efficacy has not yet been proven because no clinical investigations with IKg channel blockers are known. The "particularly rapidly" activating and very slowly inactivating component of the delayed rectifier IKjr (=ultra-rapidly activating delayed rectifier), which corresponds to the Kv1.5 channel, plays a particularly large part in the repolarization time in the human atrium. Inhibition of the IKur potassium outward current thus represents by comparison with inhibition of IKr or IKs a particularly effective method for prolonging the atrial action potential and thus for terminating or preventing atrial arrhythmias. Mathematical models of the human action potential suggest that the beneficial effect of blockade of the IKji- ought to be particularly pronounced precisely under the pathological conditions of chronic atrial fibrillation (M. Courtemanche, R. J. Ramirez, S. Nattel, Cardiovascular Research 1999, 42, 477-489: "Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model"). In contrast to IKf and IKQ, which also occur in the human ventricle, although IKu1 plays a significant part in the human atrium it does not in the ventricle. For this reason, when the IKur current is inhibited, in contrast to blockade of IKf or IKs, the risk of a proarrhythmic effect on the ventricle is precluded from the outset. (Z. Wang et at., Circ. Res. 73, 1993, 1061 -1076; "Sustained Depolarisation-lnduced Outward Current in Human Atrial Myocytes"; G.-R. Li et al., Circ. Res. 78, 1996, 689 - 696: "Evidence for Two Components of Delayed Rectifier K+-Current in Human Ventricular Myocytes"; G. J. Amos et al., J. Physiol. 491,1996, 31 - 50: "Differences between outward currents of human atrial and subepicardial ventricular myocytes"). Antiarrhythmics which act via selective blockade of the IKur current or Kvl .6 channel have not to date been available on the market. Although numerous active pharmaceutical ingredients (e.g. tedisamil, bupivacaine or sertindole) have tseen described to have a blocking effect on the Kv1.5 channel, in each of these cases the Kvl .5 blockade is only a side effect in addition to other principal effects of the substances. WO 98 04 521 and WO 99 37 607 claim aminoindanes and aminotetrahydro-naphthalenes as potassium channel blockers which block the Kvl .5 channel. Likewise claimed as Kvl .5 blockers are structurally related aminochromans in WO 00 12 077. Thiazolidinones which likewise block the potassium channel are claimed in the application WO 99 62 891. The use of various pyridazinones and phosphine oxides as antiarrhythmics which are said to act via IKj1 blockade is claimed in the applications WO 98 18 475 and WO 98 18 476. However, the same compounds were originally also described as immunosuppressants (WO 96 25 936). All the compounds described in the abovementioned applications have structures which are completely different from the compounds of the invention in this application. We are not aware of any clinical data for any of the compounds claimed In the abovementioned applications. Since experience shows that only a small fraction of active Ingredients from preclinical research successfully overcomes all the clinical hurdles leading to a medicament, there is still a need for promising substances. It has now been found, surprisingly, that the anthranilamides of the invention of the formula I are potent blockers of the human Kvl .5 channel. They can therefore be used as novel antiarrhythmics with a particularly advantageous safety profile. The compounds are particularly suitable for treating supraventricular arrhythmias, e.g. atrial fibrillation or atrial flutter. The compounds can be employed for terminating existing atrial fibrillation or flutter to return to sinus rhythm (cardioversion). In addition, the substances reduce the susceptibility to recurrence of fibrillation events {retention of sinus rhythm, prophylaxis). The compounds of the invention have not previously been disclosed. Some structurally related compounds are described in the publications discussed hereinafter. Thus, for example, compounds A and B were mentioned in FEBS Letters 421 (1981) 217-220 as serine protease Inhibitors. Compounds C and D, and similar derivatives are described in J. Med. Chem. 11 (1968) 777-787 as precursors for synthesizing tetrahydroisoquino[2,1 -d][1,4] benzodiazepines. n c1U 0=s=o European patent application EP-A 0 686 625 describes anthranllic acid derivatives and their use as cGMP phosphodiesterase inhibitors. Most of the 144 compounds described by way of example therein differ from the compounds of the formula I inter alia through replacement of the sulfonyl group by a carbonyl group. Only 3 of the examples likewise contain a sulfonylamino substitution, of which compound E (example 135 in EP-A 0 686 625) comes closest in structure to the compounds in this application. Possible indications mentioned for the claimed compounds are ischemic heart disease, angina pectoris, hypertension, pulmonary hypertension, heart failure and asthma. This by no means makes It obvious that these or similar compounds can be used as antiarrhythmics. I °'xxl"Xc:> European patent application EP-A 0 947 500 claims a large, somewhat heterogeneous, quantity of compounds which are said to act as prostaglandin E2 antagonists or agonists. Most of the anthranilio acid derivatives present therein differ from the compounds of this application inter alia through the presence of a free carboxyl function. European patent application EP-A 0 491 525 describes anthranilamides with various 5-membered heretocycles in the side chain, such as, for example, the compound F, and the use thereof for treating diabetes. A potassium channel-blocking action Is not mentioned in any of these publications mentioned, so that the effect of the structurally related compounds of the formula I could not have been expected. The present invention relates to compounds of the formula I, R(9) is hydrogen or alky! having 1 or 2 carbon atoms; R(10) is hydrogen or alkyl having 1 or 2 carbon atoms; R(11) is cycloalkyi having 3, 4, 5 or 6 carbon atoms, phenyl, where phenyl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, CF3, OCF3, CN, COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R{13) isCpH2p-R(14); p isO, 1,2, 3 or 4; R(14) is aryl or heteroaryl, where aryl and heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R(2) is hydrogen; R(3) is alkyl having 3, 4 or 5 carbon atoms, phenyl, where phenyl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, CF3, OCF3, COOMe, CONH2, COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R(4), R(5), R(6) and R(7) are, independently of one another, hydrogen, F, CI, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; and the pharmaceutical ly acceptable salts thereof. Alkyl radicals and alkylene radicals may be straight-chain or branched. This also applies to the alkylene radicals of the formulae CnHgn- CmH2m 111 CpH2p. Alkyl radicals and alkylene radicals may also be straight-chain or branched if they are substituted or present in other radicals, e.g. in an alkoxy radical or in a fluorinated alkyl radical. Examples of alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3,3-dimethylbutyl, heptyl. The divalent radicals derived from these radicals, e.g. methylene, 1,1-ethylene, 1,2-ethylene, 1,1-propylene, 1,2-propylene, 2,2-propyiene, 1,3-propylene, 1,1-butylene, 1,4-butylene, 1,5-pentylene, 2,2-dimethyl-1.3-propylene, 1,6-hexylene etc., are examples of alkylene radicals. CycloalkyI radicals may likewise be branched. Examples of cycloalkyi radicals having 3 to 7 carbon atoms are cyclopropyl, cyclobutyl, 1-methylcyclopropyl, 2-methyJcyclopropyl, cyclopentyl, 2-methylcyciobutyl. 3-methylcyclobutyl, cyclopentyl, cyclohexyl, 2-methylcyciohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cycloheptyl etc. Heteroaryl radicals are, in particular, 2- or 3-thienyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4-or 5-imidazolyl, 1-, 3-, 4-or5-pyrazolyl, 1,2,3-triazol-1-,-4-or5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 1,2,3-oxadia20l-4- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-oxadiazol-2-yl or -5-yl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isofhiazo(y(, 1,3,4-fhiadiazo(-2- or -5-y(, 1,2,4-fhiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or 5-yl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 3- or 4-pyridazinyl, pyrazinyl, 1 -, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1 -, 2-, 4- or 5-benzimidazolyl, 1 -, 3-, 4-, 5-, 6- or 7-indazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-Isoquinolyi, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 3-, 5-, 6-, 7- or 8-quinoxalinyl, 1-, 4-, 5-, 6-, 7- or 8-phthalazinyl. The corresponding N-oxides of these compounds are also included, that is to say, for example, 1-oxy-2-, 3- or 4-pyridyl. Particular preference is given to the heteroaromatic systems thienyl, furyl, pyrrolyl, imidazolyl, quinolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl. Pyridyl means 2-, 3- and 4-pyridyl. Thienyl means both 2- and 3-thienyl. Furyl means both 2- and 3-fury(. Aryl is phenyl and 2- or 3-naphthyl. Monosubstituted phenyl radicals may be substituted in the 2, 3 or 4 position, disubstituted in the 2,3, 2,4, 2,5, 2,6, 3,4 or 3,5 positions, trisubstituted in the 2,3,4, 2,3,5, 2,3,6, 2,4,5, 2,4,6 or 3,4,5 positions. Corresponding statements also apply analogously to the N-containing heteroaromatic systems, the naphthyl, thiophene or furyl radical. In the case of di- or trisubstitution of a radical, the substituents may be identical or different. If the compounds of the formula I contain one or more acidic or basic groups or one or more basic heterocycles, the invention also includes the corresponding physiologically or toxicologically acceptable salts, in particular the pharmaceutically utilizable salts. Thus, the compounds of the formula I which have acidic groups, e.g. one or more COOH groups, can be used for example as alkali metal salts, preferably sodium or potassium salts, or as alkaline earth metal salts, e.g. calcium or magnesium salts, or as ammonium salts, e.g. as salts with ammonia or organic amines or amino acids. With compounds of the formula I in which R2 is hydrogen it is possible, for example, for the sulfonamide function to be deprotonated to form a sodium salt. Compounds of the formula I which have one or more basic, i.e. protonatable, groups or contain one or more basic heterocyclic rings can also be used in the form of their physiologically tolerated acid addition salts with inorganic or organic acids, for example as hydrochlorides, phosphates, sulfates, methanesulfonates, acetates, lactates, maleates, fumarates, malates, gluconates etc. If the compounds of the formula I contain t>oth acidic and basic groups in the molecule, the invention includes not onJy the salt forms described but also inner salts, called betaines. Salts can be obtained from the compounds of the formula I by conventional processes, for example by combining with an acid or base in a solvent or dispersant or else by anion exchange from other salts. The compounds of the formula I may when appropriately substituted exist in stereoisomeric forms. If the compounds of the formula I contain one or more centers of asymmetry, these may have, independently of one another, the S configuration or the R configuration. The invention includes all possible stereoisomers, e.g. enantiomers or diastereomers, and mixtures of two or more stereoisomeric forms, e.g. enantiomers and/or diastereomers, in any ratios. The invention thus includes, for example, enantiomers in enantiopure form, both as levorotatory and as dextrorotatory antipodes, and in the form of mixtures of the two enantiomers in various ratios or in the form of racemates. Individual stereoisomers can be prepared if required by fractionating a mixture by conventional methods or, for example, by stereoselective synthesis. If mobile hydrogen atoms are present, all tautomeric forms of the compounds of the formula I are also encompassed by the present invention. The compounds of the formula I can be prepared by various chemical processes, some examples of which are outlined as scheme 1 or 2 below. The radicals R(1) to R(7) used herein are In each case defined as indicated above. As shown in scheme 1, compounds of the invention can be prepared, for example, by initially reacting an amino carboxylic acid of the formula II in a solvent such as water, pyridine or an ether in the presence of a base with a sulfonyl chloride of the formula R(3)-S02-CI or a sulfonic anhydride. Suitable as base are inorganic bases such as, for example, sodium carbonate or potassium hydroxide or organic bases such as, for example, pyridine or triethylamine. The resulting sulfonylamino carboxylic acid of the formula III can then be activated, for example by reaction with a chlorinating agent such as, for example, phosphorus pentachloride, phosphorus oxychloride or thionyl chloride, in an inert solvent to give an acid chloride and then be reacted with an amine of the formula H-R1 to give the title compounds of the formula I. However, activation of the carboxyl group in the compound of the formula III can also take place in a different way, for example by one of the numerous methods familiar to the skilled worker and used in peptide chemistry / for forming amide bonds, for example by conversion into a mixed anhydride or an activated ester or with use of a carbodiimide such as dicyclohexylcarbodiimde. The reaction of the activated sulfonylamino carboxylic acid with an amine of the formula H-R1 is advantageously carried out in an inert solvent such as, for example, pyridine, tetrahydrofuran or toluene without addition or with addition of an inert base, for example a tertiary amine or pyridine. R7 ,S = 0 O" R3 R4 O NH R7 R2 -ei1ssR1 R4 O R4 O Scheme 1 Alternatively, as shown in scheme 2, it is also possible initially to react the anhydrides of the formula IV with an amine of the formula H-R1 to give an o-aminobenzamide of the formula VII, from which a compound of the formula I is then obtained by reaction with a sulfonyl chloride of the formula R(3)S02CI. Another possibility for preparing intermediates of the formula VII in which R(2} is hydrogen comprises the amidation of an o-nitrobenzoic acid of the formula V with an amine of the formula HNR(1)R(2), followed by reduction of the nitro group to the amine. / N 1O R4 0 R7,1Ba H-R1 R1 M*'° H2. Pd N H-R1 1 R6 R(3)S02Ct R4 0 Scheme 2 R4 O R7 O VI R4 0 It may be appropriate in all the procedures to protect functional groups in the molecule temporarily during certain reaction steps. Such protective group techniques are familiar to the skilled worl The compounds of the invention of the formula I and their physiologically tolerated salts can thus be used on animals, preferably on mammals and, in particular, on humans as pharmaceuticals on their own or in mixtures with one another or in the form of pharmaceutical preparations. The present invention also relates to compounds of the formula I and their physiologically tolerated salts for use as phamnaceuticals, to their use in the therapy and prophylaxis of the pathological states mentioned and to their use for producing medicaments therefor and medicaments with K+ channel-blocking effect. The present invention further relates to pharmaceutical preparations which comprise as active ingredient an effective dose of at least one compound of the formula I and/or a physiologically tolerated salt thereof in addition to conventional pharmaceutically acceptable carriers and excipients. The pharmaceutical preparations normally contain from 0.1 to 90% by weight of the compounds of the formula I and/or their physiologically tolerated salts. The pharmaceutical preparations can be produced in a manner known per se. For this purpose, the compounds of the formula I and/or their physiologically tolerated salts are converted together with one or more solid or liquid pharmaceutical carriers and/or excipients and, if desired, In combination with other active pharmaceutical ingredients into a suitable administration form or dosage form which can then be used as pharmaceutical in human medicine or veterinary medicine. Pharmaceuticals which comprise compounds of the invention of the formula I and/or their physiologically tolerated salts can be administered orally, parenterally, e.g. intravenously, rectally, by inhalation or topically, the preferred administration depending on the individual case, e.g the particular manifestation of the disease to be treated. The excipients suitable for the desired pharmaceutical formulation are familiar to the skilled worker on the basis of his expert knowledge. Besides solvents, gel formers, suppository bases, tablet excipients and other active ingredient carriers it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers, agents to achieve a depot effect, buffer substances or colorants. The compounds of the formula I can also be combined with other active pharmaceutical ingredients to achieve an advantageous therapeutic effect. Thus, in the treatment of cardiovascular disorders, combinations with substances acting on the cardiovascular system are possible and advantageous. Such combination partners advantageous for cardiovascular disorders are, for example, other antiarrhythmics, i.e. class I, class II or class III antiarrhythmics, such as, for example, IKs- or IKp channel blockers, e.g. dofetilide, or, in addition, hypotensive substances such as ACE inhibitors (for example enalapril, captopril, ramipril), angiotensin antagonists, K+ channel activators, and alpha- and beta-receptor blockers, as well as sympathomimetic and adrenergic compounds, and Na+/H+ exchange inhibitors, calcium channel blockers, phosphodiesterase inhibitors and other substances with a positive inotropic effect, such as, for example, digitalis glycosides, or diuretics. For a form for oral use, the active compounds are mixed with the additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into the suitable administration forms such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily solutions. Examples of inert carriers which can be used are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. Preparation is possible in this connection both as dry and as wet granules. Suitable as oily carriers or as solvents are, for example, vegetable or animal oils, such as sunflower oil or fish liver oil. Examples of suitable solvents for aqueous or alcoholic solutions are water, ethanol or sugar solutions or mixtures thereof. Further examples of excipients, also for other administration forms, are polyethylene glycols and polypropylene glycols. For subcutaneous or intravenous administration, the active compounds are converted into a solution, suspension or emulsion, if desired with the substar1ces customary for this purpose, such as solubilizers, emulsifiers or other excipients. The compounds of the formula I and their physiologically tolerated salts can also be lyophilized and the resulting lyophilizates be used for example to produce products for injection or infusion. Examples of suitable solvents are water, physiological saline or alcohols, e.g. ethanol, propanol, glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else mixtures of the various solvents mentioned. Suitable as pharmaceutical formulation for administration In the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active ingredients of the formula I or of their physiologically tolerated salts in a pharmaceutically acceptable solvent such as, in particular, ethanol or water, or a mixture of such solvents. The formulation can if required also contain other pharmaceutical excipients such as surfactants, emulsifiers and stabilizers, and a propeliant gas. Such a preparation normally contains the active ingredient in a concentration of about 0.1 to 10, in particular of about 0.3 to 3, percent by weight. The dosage of the active ingredient of the formula I to be administered or of the physiologically tolerated salt thereof depends on the individual case and should be adapted in a conventional way to the circumstances of the individual case for an optimal effect. Thus, of course, it depends on the frequency of administration and on the potency and duration of action of the compounds employed in each case for therapy or prophylaxis, but also on the nature and severity of the disease to be treated and on the sex, age, weight and individual response of the human or animal to be treated and on whether the therapy is acute or prophylactic. The daily dose of a compound of the formula I is normally, on administration to a patient weighing about 75 kg, from 0.001 mg/kg of bodyweight to 100 mg/kg of bodyweight, preferably 0.01 mg/kg of bodyweight to 20 mg/kg of bodyweight. The dose can be administered in the form of a single dose or else be divided into a plurality of, e.g. two, three or four single doses. Especially in the treatment of acute cases of cardiac arrhythmias, for example on an intensive care ward, parenteral administration by injection or Infusion, e.g. by a continuous intravenous infusion, may also be advantageous. Experimental part List of abbreviations DMAP 4-dimethylaminopyridine DMF N,N-dimethylformamide EDAC N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride EA ethyl acetate HOBT 1-hydroxy-1H-benzotriazole RT room temperature THF tetrahydrofuran BuLi butyllithium General method 1: Reaction of anthranilic acids with sulfonyl chlorides to give o-sulfonylaminobenzoic acids (analogous to Organic Syntheses 1952, 32, 8) 1.2 mol of the appropriate sulfonyl chloride are added in portions at 60°C to a solution of 260 g (2.4 mol) of sodium carbonate and 1 mol of the appropriate anthranilic acid in 1.5 I of water. The reaction mixture is heated at 60-80°C until the reaction is complete (about 1-6 h), adding further sulfonyl chloride if necessary. After cooling, the reaction mixture is poured into 500 ml of 6 molar hydrochloric acid, and the precipitate is filtered off with suction and dried in vacuo in an oven at 45°C. If the product does not result as crystals, it is isolated by extraction with ethyl acetate. Precursor 1 a: 2-(Toluene-4-sulfonylamino)benzoic acid 9.6 g of the title compound were obtained as a white solid from 6.85 g of anthranilic acid and 10.5 g of para-toluenesulfonyl chloride by general method 1. MS{ES):293(M+1). Precursor 1 b: 2-Butylsulfonylamino-5-methylbenzoic acid 4.2 g of 2-butylsulfonylamino-5-methylbenzoic acid were obtained from 5 g of 5-methylanthranilic acid and 6.2 g of butanesulfonyl chloride by general method 1. MS(ES):272(M+1). Precursor 1 c: 2-{4-Methoxybenzenesulfonylamino)-6-methylbenzoic acid / Precursor 2 a: 2-(4-Toluenesulfonylamino)benzoyl chloride 7.5 g of the title compound were isolated as white solid from 9.6 g of 2-(toluene-4-sulfonylamino)benzoic acid (precursor 1 a) and 8.3 g of phosphorus pentachloride. IVIS (ES, detected as methyl ester after addition of methanol): 306 (l\1+1). B) with thionyl chloride 8 mmol of the sulfonylaminobenzoic acid are heated in 6 ml of thionyl chloride at 60°C for 3 h, and concentrated, and the residue is coevaporated twice with toluene. Precursor 2 b: 2-(4-Methoxybenzenesulfonylamino)benzoyl chloride NH I 0=S a 1CI "1 o 2.2 g of the title compound were obtained from 2.4 g of 2-(4-methoxybenzenG- sulfonylamino)benzoic acid and 5 ml of thionyl chloride. MS (ES, detected as methyl ester after addition of methanol): 322 (M+1). acetic acid, stirred at room temperature for 6 h. The solution is concentrated, taken up in ethyl acetate and washed twice with NaHCOs solution. The organic phase is concentrated, and the residue is distilled under high vacuum. In the case of involatile secondary amines, volatile constituents are distilled off and the residue is dissolved in ether/THF and, after addition of ethereal HCI solution, the precipitated hydrochloride is filtered off with suction, washed with ether and dried. The prepared secondary amines were employed without further purification for the reactions with the sulfonylaminobenzoyi chlorides or sulfonylaminobenzoic acids. Precursor 3 a: Benzyl(1-methyl-1 H-imidazol-2-ylmethyi)amine The hydrochloride (20.5 g) was prepared from 19.4 g of benzylamine and 10 g of 2-formyl-1-methylimida2ole by the general procedure. MS(ES+):m/z = 202(M+1). Precursor 3 b: Benzylpyrldin-3-ylmethylamine The secondary amine (2.8 g) was prepared by the general procedure from 4.32 g of 3-pyridylmethylamine and 2.12 g of benzaldehyde after Kugelrohr distillation under 0.1 mbarat 130°C. MS(ES+):m/z=199(M+1). General method 3 B: Preparation of a-branched annines from ketones A solution of 67 mmol of the appropriate ketone in 120 ml of ethanol is added dropwise to a solution of 200 mmol of hydroxylammonium chloride and 200 ml of sodium acetate in 120 ml of water at 30°C, and the mixture is heated at SO'C until reaction is complete {1-3 h). After cooling, the reaction mixture is diluted with water, and the precipitated oxide is filtered off with suction or, if necessary, isolated by extraction. The resulting product is dissolved in 100 ml of methanol, 100 ml of THF and 10 ml of concentrated ammonia solution and hydogenated in the presence of Raney nickel at RT under atmospheric pressure until hydrogen uptake ceases. Removal of the catalyst by filtration and concentration of the reaction mixture results in the corresponding amine which is purified by chromatography if necessary. Precursor 3 1:1-Benzylpropylamine 4.5 g of the title compound were obtained from 10 g of 1-phenyI-2-butanone by general method 3. Precursors m; 1-Pyridin-4-ylpropyIamine N\1 10.2 g of the title compound were obtained from 10 g of 4-propionylpyridine by general method 3 B. Precursor 3 n : 1-Pyridin-3-yl-propylamine 0.9 g of the title compound was obtained from 1 g of 4-propionylpyridine by general method 3 B. Precursors s: 1-Cyclopropyl-1-phenylmethylamine hydrochloride H1N a) N-(Cyclopropylphenylmethyl)formamide 14.8 g (0.1 mol) of cyclopropyi phenyl ketone, 11.4 ml (0.3 mol) of formic acid and 20 ml (0.5 mol) of formamide were heated at 160°C for 18 h. After cooling, 10O ml of water were added and the mixture was extracted 2x with 50 ml of ether each tinrie. The ethereal phase was washed with 50 ml of 10 % Na2C03 solution, dried over Na2S04 and concentrated. 13.6 g (77.4 mmol) of a yellow oil were obtained. b) 1-Cyclopropyl-1-phenylmethylamine hydrochloride 13.6 g (77.4 mmol) of N-(cyclopropylphenylmethyl)formamide (see a) were heated to reflux in 100 ml of 2N HCl for 18 h. After cooling, the mixture was extracted 2x with 50 ml of dichloromethane each time, and the aqueous phase was concentrated. The residue was taken up in 30 ml of 2-propanol, heated to boiling and cooled in a refrigerator overnight. The crystals of 1 -cyclopropyi-1 -phenylmethylamine hydrochloride which had separated out (3.85 g, 21 mmol) were filtered off with suction and dried in a vacuum oven. Precursor 31: Cyclopropylpyridin-2-yl-methylamine hydrochloride a)Cyclopropylpyridin-2-ylmethyleneamlne 25 g (157.5 mmol) of 2-bromopyridlne in 100 ml of diethyl ether were added dropwise over the course of 20 min to 100 ml (160 mmol) of n-BuLi solution in 300 ml of diethyl ether at -70°C. The dark red solution was stirred for 5 h and then 8.8 g (131 mmol) of cyclopropanecarbonitrile in 100 m! of ether were added. The mixture was stirred at -70'C for 30 min, warmed to room temperature and stirred for a further 30 min. Then 15 g of Na2S04 x 10 H2O were added, and stirring was continued for 1 h. The red solution was mixed with Na2S04, filtered and concentrated. The product was distilled in a Kugelrchr apparatus at 75°C-120°C/0.3mbar as a pale yellow oil (18.6 g, 127 mmol) and was stored at -IS1C. b) Cyclopropylpyridin-2-ylm6thylan\in6 hydrochloride 2.72 g (18.6 mmol) of cyclopropylpyridin-2-ylmethyleneamine (see a) were dissolved in 35 ml of dry methanol. At 0°C, 0.69 g (18.6 mmol) of NaBH4 was added in portions. After 30 min at 0°C, the mixture was stirred at room temperature for 2 h and, after adjustment to pH 3 with 1M HCI, the methanol was stripped off in a rotary evaporator and the residue was freeze-dried. 8.8 g of cyclop ropylpyridin-2-ylmethy la mine hydrochloride mixed with inorganic salts and boric acid were obtained. Precursor 3 u: Cyclopropylpyridin-3-ylmethylamine hydrochloride a) Cyclopropylpyridin-3-ylmethyleneamine 7.5 g (51 mmol) of the imine were isolated as a yellow oil in accordance with the method for precursor 3 p starting from 8.8 g (131 mmol) of cyclopropanecarbonitrile, 25 g (157.5 mmol) of 3-bromopyridine and 173 mmol of n-BuLi solution and after Kugelrohr distillation (130°C/0.2mbar). b) Cyclopropylpyridin-3-ylmethylamine hydrochloride 16.6 g of cyclopropylpyridin-3-yln:iethylamine hydrochloride mixed with inorganic salts and boric acid were obtained in accordance with the method for precursor 3 p starting from 7.5 g (51.5 mmol) of imine (see a) and 1.9 g (51.4 mmol) of NaBH4. Precursor 3 v: 1-(5-Methylfuran-2-yl)propylamine "■1 11.35 g (180 mmol) of sodium cyanoborohydride were introduced in portions into 5 g (36 mmol) of 2-metbyl-5-propionylfuran and 28.2 g (366 mmol) of ammonium acetate in 300 ml of methanol with stirring and left to react at RT for 18 h. The mixture was substantially concentrated and, after addition of 200 ml of dichloromethane, the organic phase was washed 3x with 50 ml of NaHCOs solution each time, dried over Na2S04 and concentrated. 3.9 g (28 mmol) of the amine were obtained in the fonn of a pale yellow oil. Precursor 3 w: 1-Phenylprop-2-ynylamine hydrochloride H1N' The compound was prepared in accordance with the method of Bjom M. Nilsson et al., J. Heterocycl. Chem. (1989), 26(2), 269-75 starting from 1-phenyl-2-propynyl alcohol by a Rltter reaction and subsequent hydrolysis with hydrochloric acid. Precursor 3 x: C-Cyclopropyl-C-(6-methoxypyridin-2-yl)methylamine N1O1 a) Cyclop ropanecarbaldehyde 0-benzyloxime 6.7 g {95.6 mmoi) of cyclopropanecarbaldehyde were stirred together with 15.3 g (95.6 mmol) of 0-benzylhydroxylamine and 15.7 g (191.2 mmol) of sodium acetate in 250 ml of ethanol at room temperature for 18 h and, after concentration, Na2S04 was added. The residue was extracted 3x with 50 ml of dichloromethane each time, the organic phase was concentrated, and the crude product was purified by chromatography on silica gel. 5 g (28.6 mmol) of a colorless liquid were obtained. b) 0-Benzyl-N-[cyclopropyl-(6-methoxypyridin-2-yl)methyl]hydroxyiamine 8.8 ml (22 mmol) of n-BuLi (2.5 M in toluene) were added to 3.76 g (20 mmol) of 2-bromo-6-methoxypyridine in 20 ml of THF at -TSX. After 30 min, this dark red solution was added to a solution of 1.4 g {8 mmol) of cyclopropanecarbaldehyde 0-benzyloxime (see a) and 2.52 ml (20 mmol) of BF3 etherate in 40 ml of toluene which had been stirred at -78°C for 15 min. The mixture was stirred at -78°C for 4 h, slowly warmed to RT and, after addition of water, made alkaline with saturated Na2C03 solution. The organic phase was separated off, the aqueous phase was extracted with toluene, and the combined organic phases were dried over Na2S04 and concentrated. The crude product was taken up in 12 ml of acetonltrlle, insolubles were removed, and the product was isolated by preparative HPLC (650 mg, red oil). c) C-Cyclopropyl-C-(6-methoxypyridin-2-yl)methylamine 650 mg (2.3 mmol) of 0-bGnzyl-N-[cyclopropyl-(6-methoxypyridin-2-yl)methyl]-hydroxylamine (see b) were dissolved in 18 ml of glacial acetic acid and diluted with / 18 ml of water. 3.3 g of zinc dust were added, and the suspension was reacted in an ultrasonic bath for 24 h. The mixture was filtered through kieselguhr, washed with 50% acetic acid, and the filtrate was partially evaporated and adjusted to pH 11 with saturated NagCOs solution. It was extracted 3x with 100 ml of dichloromethane each time, dried over Na2S04 and concentrated. 0.4 g (2.2 mmol) of the product was obtained in the form of a dark red oil. General method 4 A: Preparation of 2-aminobenzamides from 2-nitrobenzoic acids The appropriate 2-nitrobenzoic acid is initially reacted in analogy to general methods 2 and 5 with the respective amine to give a 2-nitrobenzamide. Then 4 mmol of the 2-nitrobenzamlde are hydrogenated in 50 ml of THF and 50 ml of methanol in the presence of a spatula tip of 10% palladium on carbon at RT under atmospheric pressure. The catalyst is filtered off with suction, the reaction mixture is concentrated, and the corresponding 2-aminobenzamtde is obtained. The following precursor was, inter alia, synthesized in this way: Precursor Structure Mass 4a "9 (V"" 318 (M+1) General method 4 B; Preparation of 2-aminobenzamides from isatoic anhydride A solution of 20 mmol of isatoic anhydride and 22 mmol of the appropriate amine in 75 ml of DMF is heated at 60°C until reaction is complete. 100 ml of water are added to the reaction mixture, and the product is filtered off with suction or isolated by extraction. Precursor 4 b; (S)-2-Amino-N-{1-phenylpropyl)benzamide 3.4 g of the title compound were obtained from 3 g of (S)-l-phenylpropylamine and 3.2 g of Isatoic anhydride after 2 h at 60°C in accordance with general method 4 b. General method 5: Reaction of sulfonylaminobenzoyl chlorides with amines 0.6 mmol of the particular sulfonylaminobenzoyl chloride is added to a solution of 0.66 mmol of the particular amine and 0.9 mmol of triethylamine in 3 ml of methylene chloride, and the mixture is stirred at room temperature overnight. The reaction mixture is diluted with 5 ml of water and 10 ml of methylene chloride, and the organic phase is washed successively with 1M hydrochloric acid solution and saturated sodium bicarbonate solution. After drying over magnesium sulfate, the solution is concentrated in vacuo, and the product is purified as necessary by preparative HPLC or column chromatography. Example 1: (S)-2-Phenylsulfonylamino-5-chloro-N-(1-phenylethyl)benzamide Example 6: (R)-2-Phenylsulfonylamino-5-chloro-N-[1 -(4-melhoxyphenylethyl]-benzamide Xn1. 0=3=0 112 mg of the title compound were obtained from 2-phenylsulfonylamino-5-chloro-benzoyl chloride artd R-(+)-1-(4-methoxyphenyl)ethylamine in accordance with general method 5. MS (ES+): m/z = 445 {M+1). Example 7: 2-Phenylsulfonylamino-5-chloro-N-(phenylpyridin-2-ylmethyl)benzamide 211 mg of the title compound were obtained from 2-phenylsulfonylamino-5-chlorobenzoyl chloride and C-phenyl-C-pyridin-2-ylm0thylamine in accordance with general method 5. MS (ES+): m/z = 478 (M+1). mixture is diluted with EA and washed with dilute hydrochloric acid and sodium bicarbonate solution. Drying over magnesium sulfate and concentrating in vacuo result in the appropriate amide which is purified if necessary by preparative HPLC Beispiel54:2-(Butylsulfonylamino)-N-cyclohexyl-5-methylbenzamide 184 mg of the title compound were obtained from 200 mg of 2-butylsulfonylamino-5-methylbenzoic acid (precursor 1 b) and cyclohexylamine in accordance with general method 6. MS (ES+): m/z = 353 (M+1). General method 7: Reaction of 2-aminobenzamides with sulfonyl chlorides A solution of 0.3 mmol of the appropriate sulfonyl chloride in 2 ml of methylene chloride is added dropwise to a solution of 0.2 mmol of the appropriate 2-aminobenzam)de (precursor 4) and 0.6 mmol of pyridine in 5 ml of methylene chloride at 0°C, and the mixture is stirred at RT overnight. The organic phase is washed with water, dilute hydrochloric acid and sodium bicarbonate solution, and the resulting crude product is purified If necessary by preparative HPLC. The 3-methylbutylsulfonyl chloride required for example 74 was prepared from 3-methylbutyl bromide by reaction with ammonium sulfite solution under reflux to give the sulfonic acid, followed by chlorination with phosphorus pentachloride to give the B sulfonyl chloride. The following compounds were additionally obtained in analogy to the above examples and by use of one or more of general methods 1-7: The following further examples were prepared in accordance with general method 5: The compound was obtained from the compound of example 90 by cleavage of the methyl ether with boron tribromide. Pharmacological investigations Human Kvl .5 channels were expressed in xenopus oocytes. For this purpose, firstly oocytes were isolated from Xenopus laevis and were defolliculated. Kvl .5-encoding RNA which had been synthesized in vitro was then injected into these oocytes. After 1-7 days of Kvl .5 protein expression, the Kvl .5 currents were measured on the oocytes by the two-microelectrode voltage clamp technique. The Kv1.5 channels were for this purpose usually activated with voltage jumps lasting 500 ms to 0 mV and 40 mV. A solution of the following composition flowed through the bath: NaCl 96 ivU, KCI 2 mM, CaCl2 1.8 mM, MgClg 1 mM, HEPES 5 mM (titrated to pH 7.4 with NaOH). These experiments were carried out at room temperature. The following were employed for data acquisition and analysis: geneclamp amplifier (Axon Instruments, Foster City, USA) and MacLab D/A converter and software (ADInstruments, Castle Hill, Australia). The substances of tfie invention were tested by adding them in various concentrations to the bath solution. The effects of the substances were calculated as percentage inhibition of the Kvl .5 control current which was obtained when no substance was added to the solution. The data were then extrapolated using the Hill equation in order to determine the inhibitory concentrations IC50 for the respective substances. The following IC50 values were determined in this way for the compounds listed below: mixture is diluted with EA and washed with dilute hydrochloric acid and sodium bicarbonate solution. Drying over magnesium sulfate and concentrating in vacuo result in the appropriate amide which is purified if necessary by preparative HPLC Beispiel54:2-(Butylsulfonylamino)-N-cyclohexyl-5-methylbenzamide 184 mg of the title compound were obtained from 200 mg of 2-butylsulfonylamino-5-methylbenzoic acid (precursor 1 b) and cyclohexylamine in accordance with general method 6. MS (ES+): m/z = 353 (M+1). General method 7: Reaction of 2-aminobenzamides with sulfonyl chlorides A solution of 0.3 mmol of the appropriate sulfonyl chloride in 2 ml of methylene chloride is added dropwise to a solution of 0.2 mmol of the appropriate 2-aminobenzam)de (precursor 4) and 0.6 mmol of pyridine in 5 ml of methylene chloride at 0°C, and the mixture is stirred at RT overnight. The organic phase is washed with water, dilute hydrochloric acid and sodium bicarbonate solution, and the resulting crude product is purified If necessary by preparative HPLC. The 3-methylbutylsulfonyl chloride required for example 74 was prepared from 3-methylbutyl bromide by reaction with ammonium sulfite solution under reflux to give the sulfonic acid, followed by chlorination with phosphorus pentachloride to give the B sulfonyl chloride. The following compounds were additionally obtained in analogy to the above examples and by use of one or more of general methods 1-7: The following further examples were prepared in accordance with general method 5: The compound was obtained from the compound of example 90 by cleavage of the methyl ether with boron tribromide. Pharmacological investigations Human Kvl .5 channels were expressed in xenopus oocytes. For this purpose, firstly oocytes were isolated from Xenopus laevis and were defolliculated. Kvl .5-encoding RNA which had been synthesized in vitro was then injected into these oocytes. After 1-7 days of Kvl .5 protein expression, the Kvl .5 currents were measured on the oocytes by the two-microelectrode voltage clamp technique. The Kv1.5 channels were for this purpose usually activated with voltage jumps lasting 500 ms to 0 mV and 40 mV. A solution of the following composition flowed through the bath: NaCl 96 ivU, KCI 2 mM, CaCl2 1.8 mM, MgClg 1 mM, HEPES 5 mM (titrated to pH 7.4 with NaOH). These experiments were carried out at room temperature. The following were employed for data acquisition and analysis: geneclamp amplifier (Axon Instruments, Foster City, USA) and MacLab D/A converter and software (ADInstruments, Castle Hill, Australia). The substances of tfie invention were tested by adding them in various concentrations to the bath solution. The effects of the substances were calculated as percentage inhibition of the Kvl .5 control current which was obtained when no substance was added to the solution. The data were then extrapolated using the Hill equation in order to determine the inhibitory concentrations IC50 for the respective substances. The following IC50 values were determined in this way for the compounds listed below: WE CALIM: 1. A compound of the formula I, A is -CnH2n-; n isO 1,2, 3, 4 or 5; O is oxygen; D is a bond or oxygen; E is -CmH2m-; m isO, 1,2,3,4 or 5; R(8) is hydrogen, alkyl having 1,2, 3 or 4 carbon atoms or CpH2p-R{14); p isO, 1,2,3.4or5; R(14) is cycloalkyl having 3, 4, 5 or 6 carbon atoms, aryl or heteroaryl, where aryl and heteroaryl are unsubstituted or substituted by 1,2 or 3 substituents selected from the group consisting of F, CI, Br, I, CF3, OCF3, NO2. CN, COOMe, CONH2, COMe, NH2. OH, alkyl having 1. 2,3 or 4 carbon atoms, alkoxy having 1,2,3 or 4 cartjon atoms, dimethyl-amino, sutfamoyi, methylsultonyl and methylsulfonylamino; R(9) is hydrogen or alkyl having 1, 2,3,4, 5 or 6 carbon atoms; R(10) is hydrogen, alkyl hawng 1,2, 3 or 4 carbon atoms, cycloalkyi having 3, 4, 5 or 6 carbon atoms, aryl or heteroaryl, where aryl and heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, Br, I, CF3. OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alkyl having 1, 2, 3 or 4 carbon atoms, aikoxy having 1, 2, 3 or 4 cart>on atoms, dimethylamino, methylsulfonyl and methylsulfonylamino; R(11) is cycloalkyi having 3.4, 5 or 6 carbon atoms, phenyl, naphthyt, thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl or pyrimidyl, where phenyl, naphthyl, thienyl. furyl, pyridyl, pyrazinyl, pyridcizinyl and pyrimidyl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, Br, I, CF3, OCF3, NO2, CN, COMe. NHg, OH, alkyl having 1, 2. 3 or 4 carbon atoms, aikoxy having 1, 2, 3 or 4 cartJon atoms, dimethylamino. sulfamoyi. methylsulfonyl and m ethylsulf onyfamino; R(12) is alkyl having 1,2,3 or 4 carbon atoms, cycloalkyi having 3,4,5 or 6 carbon atoms, aryl or heteroaryl, where aryl and heteroaryl are unsubstituted or substituted by 1,2 or 3 substituents selected from the group consisting of F. CI, Br, I, CF3, OCF3, NO2. CN, COOMe, C0rMH2, COMe, NH2, OH, alkyl having 1,2,3 or 4 carbon atoms, aikoxy having 1. 2, 3 or 4 carbon atoms, dimethylamino. sulfamoyi, methylsulfonyl and methylsulfonylamino; R(13) isCpH2p-R(14); p is 0, 1,2, 3, 4 or 5; R(14) is cycloalkyi having 3.4, 5 or 6 carbon atoms tetrahydrofuranyl, tetrahydropyranyl, aryl or heteroaryl. where aryl and heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, Br, I, CF3, OCF3, NO2. CN, COOMe, CONH2. COMe. NH2, OH, alkyl having 1, 2,3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R(15) is cycloalkyi having 3,4. 5, 6, 7 or 8 carbon atoms; R(2) is hydrogen or alkyl having 1,2, 3 or 4 carbon atoms; R(3) is alky! having 3, 4,5, 6 or 7 carbon atoms, cycloalkyi having 3, 4, 5 or 6 carbon atoms, phenyl or naphthyl, where phenyl or naphthyl are unsubstituted of substituted by 1,2 or 3 substituents selected from the group consisting of F, CI, Br, I, CF3, OCF3. NO2, CN, COOMe, C0f1H2, COMe. NH2, OH. alkyl having 1, 2. 3 or 4 carbon atoms, alkoxy having 1, 2,3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R(4), R(5), R(6) and R(7) are. independently of one another, hydrogen, F, CI. Br, I, CF3. OCF3. OCHF2, NO2. CN. COOMe, CONH2, COMe. NH2, OH, alkyl having 1. 2, 3 or 4 carbon atoms, alkoxy having 1, 2,3 or 4 cartxan atoms, dimethylamino. sutfeimoyl. methylsulfonyl and methylsulfonylamino; and the phannaceutically acceptable salts thereof. 2- The compound of the formula I as claimed in claim 1, in which: R(1)is "1NXA'°1E'-1 "1.X.'11E--1 ."\V;VE'-1 A is -CnH2n-; n isO, 1, 2.3,4 or 5; O is oxygen; D is a bond or oxygen; E is -CmH2m-i m isO, 1,2, 3, 4 or 5; R(8) is hydrogen, alkyl having 1,2, 3 or4 carbon atoms or CpH2p-R(14): p ISO, 1,2, 3, 4 or 5; R(14) is cycloalkyi having 3, 4, 5 or 6 carbon atoms, aryl or hetefoaryl. where aryl and heteroaiyl are unsubstiluted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI. Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2. OH, alkyl having 1. 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethyl-amino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R(9) is hydrogen or alkyl having 1, 2. 3, 4,5 or 6 carbon atoms; R(10) is hydrogen, alkyl having 1. 2, 3 or4 carbon atoms, cycloalkyi having 3, 4. 5 or 6 carbon atoms, aryl or heteroaryl, where aryl and heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI. Br, I. CF3, OCF3, NO2. CN, COOMe. CONH2. COMe. NH2, OH, alkyl having 1. 2. 3 or 4 cart)on atoms, alkoxy having 1, 2.3 or 4 carbon atoms, dimethylamino, sulfamoyi. methylsulfonyl and methylsulfonylamino; R(11) is cycloalkyi having 3,4, 5 or 6 carbon atoms, phenyl or pyridyl, where phenyl and pyridyl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F. CI, Br. I. CF3, OCF3. NO2. CN, COMe, NH2, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2,3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methy Isu If onylamino; R(12) is alkyl having 1, 2.3 or 4 carbon atoms, cycloalkyi having 3, 4,5 or 6 carbon atoms, aryl or heteroaryl. having 1, 2, 3 or 4 carbon atoms, drnnethylamino, sulfamoyt, methylsulfonyl and methyisulfonylamino; R{4), R(5), R(6) and R(7) are, independently of one another, hydrogen, F, CI, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, aikoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl. methylsulfonyl and methyisulfonylamino; and the phanmaceutically acceptable salts thereof. 9. A pharmaceutical preparation comprising an effectiveamountof at least one compound of the formula I as claimed in one or more of claims 1 to 6 and/or of a physiologically tolerated salt thereof as a active ingredient together with pharmaceutically acceptable carriers and additives and, where appropriate, also or more other pharmacological active ingredients.

Full Text

ANTHRANILAMIDES. PROCESS FOR THEIR PREPARATION, THEIR USE AS ANTIARRHYTHMICS, AND PHARMACEUTICAL PREPARATIONS THEREOF
The invention relates to compounds of the formula

The compounds of the invention of the formula I have not previously been disclosed. They act on the so-called Kv1.5 potassium channel and Inhibit a potassium current, which is referred to as ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore very particularly suitable as novel antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, e.g. atrial fibrillation (AF) or atrial flutter.
Atrial fibrillation (AF) and atrial flutter are the commonest persistent cardiac arrhythmias. The occurrence increases with increasing age and frequently leads to fatal sequelae such as, for example, stroke. It affects about 1 million Americans each year and leads to more than 80 000 strokes annually in the USA. The class I and til antiarrhythmics in use at present reduce the rate of recurrence of AF but are used to only a limited extent because of their potential proarrhythmic side effects. There is thus a great medical need to develop better medicaments tor the treatment of atrial arrhythmias (S. Nattel, Am. Heart J. 130,1995, 1094 -1106; "Newer developments in the management of atrial fibrillation").

It has been shown that most supraventricular arrhythmias are subject to so-called reentry waves. Such reentries occur when the cardiac tissue has a slow conductivity and, at the same time, very short refractory periods. Increasing the myocardial refractory period by prolonging the action potential is an acknowledged mechanism for terminating arrhythmias and preventing development thereof {T. J. Colatsky et al., Drug Dev. Res. 19, 1990,129 -140; "Potassium channels as targets for antiarrhythmic drug action"). The length of the action potential is essentially determined by the extent
of repolarizing K+ currents which flow out of the cells through various K+ channels. Particularly great importance is ascribed in this connection to a so-called delayed rectifier 11 which consists of 3 different components: IKf, IKs and IKur-
Most of the known class III antiarrhythmics (e.g. dofetilide, E4031 and d-sotalol) block predominantly or exclusively the rapidly activating potassium channel IK1, which can
be detected both in cells o1 the human ventricle and in the atrium. However, it has emerged that these compounds have an increased proarrhythmic risk at heart rates which are low or normal, and arrhythmias referred to as torsades de pointes have been observed in particular (D. M. Roden, Am. J. Cardiol. 72, 1993, 44B - 49B; "Current status of class III antiarrhythmic drug therapy"). Besides this high risk, which is fatal in some cases, when the rate is low, the activity of the iKr blockers has been found to decline under the conditions of tachycardia, which Is just where the effect is required ("negative use-dependence").
Whereas some of the disadvantages can possibly be overcome by blockers of the slowly activating component (IKs). their efficacy has not yet been proven because no clinical investigations with IKg channel blockers are known.
The "particularly rapidly" activating and very slowly inactivating component of the delayed rectifier IKjr (=ultra-rapidly activating delayed rectifier), which corresponds to
the Kv1.5 channel, plays a particularly large part in the repolarization time in the human atrium. Inhibition of the IKur potassium outward current thus represents by comparison with inhibition of IKr or IKs a particularly effective method for prolonging

the atrial action potential and thus for terminating or preventing atrial arrhythmias. Mathematical models of the human action potential suggest that the beneficial effect of blockade of the IKji- ought to be particularly pronounced precisely under the pathological conditions of chronic atrial fibrillation (M. Courtemanche, R. J. Ramirez, S. Nattel, Cardiovascular Research 1999, 42, 477-489: "Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model").
In contrast to IKf and IKQ, which also occur in the human ventricle, although IKu1 plays a significant part in the human atrium it does not in the ventricle. For this reason, when the IKur current is inhibited, in contrast to blockade of IKf or IKs, the risk of a
proarrhythmic effect on the ventricle is precluded from the outset. (Z. Wang et at., Circ. Res. 73, 1993, 1061 -1076; "Sustained Depolarisation-lnduced Outward Current in Human Atrial Myocytes"; G.-R. Li et al., Circ. Res. 78, 1996, 689 - 696: "Evidence for
Two Components of Delayed Rectifier K+-Current in Human Ventricular Myocytes"; G. J. Amos et al., J. Physiol. 491,1996, 31 - 50: "Differences between outward currents of human atrial and subepicardial ventricular myocytes").
Antiarrhythmics which act via selective blockade of the IKur current or Kvl .6 channel
have not to date been available on the market. Although numerous active pharmaceutical ingredients (e.g. tedisamil, bupivacaine or sertindole) have tseen described to have a blocking effect on the Kv1.5 channel, in each of these cases the Kvl .5 blockade is only a side effect in addition to other principal effects of the substances.
WO 98 04 521 and WO 99 37 607 claim aminoindanes and aminotetrahydro-naphthalenes as potassium channel blockers which block the Kvl .5 channel. Likewise claimed as Kvl .5 blockers are structurally related aminochromans in WO 00 12 077. Thiazolidinones which likewise block the potassium channel are claimed in the application WO 99 62 891. The use of various pyridazinones and phosphine oxides as antiarrhythmics which are said to act via IKj1 blockade is claimed in the applications WO 98 18 475 and WO 98 18 476. However, the same compounds were originally

also described as immunosuppressants (WO 96 25 936). All the compounds described in the abovementioned applications have structures which are completely different from the compounds of the invention in this application. We are not aware of any clinical data for any of the compounds claimed In the abovementioned applications. Since experience shows that only a small fraction of active Ingredients from preclinical research successfully overcomes all the clinical hurdles leading to a medicament, there is still a need for promising substances.
It has now been found, surprisingly, that the anthranilamides of the invention of the formula I are potent blockers of the human Kvl .5 channel. They can therefore be used as novel antiarrhythmics with a particularly advantageous safety profile. The compounds are particularly suitable for treating supraventricular arrhythmias, e.g. atrial fibrillation or atrial flutter.
The compounds can be employed for terminating existing atrial fibrillation or flutter to return to sinus rhythm (cardioversion). In addition, the substances reduce the susceptibility to recurrence of fibrillation events {retention of sinus rhythm, prophylaxis).
The compounds of the invention have not previously been disclosed. Some structurally related compounds are described in the publications discussed hereinafter.
Thus, for example, compounds A and B were mentioned in FEBS Letters 421 (1981) 217-220 as serine protease Inhibitors. Compounds C and D, and similar derivatives are described in J. Med. Chem. 11 (1968) 777-787 as precursors for synthesizing tetrahydroisoquino[2,1 -d][1,4] benzodiazepines.

n
c1U
0=s=o

European patent application EP-A 0 686 625 describes anthranllic acid derivatives and their use as cGMP phosphodiesterase inhibitors. Most of the 144 compounds described by way of example therein differ from the compounds of the formula I inter alia through replacement of the sulfonyl group by a carbonyl group. Only 3 of the examples likewise contain a sulfonylamino substitution, of which compound E (example 135 in EP-A 0 686 625) comes closest in structure to the compounds in this application. Possible indications mentioned for the claimed compounds are ischemic heart disease, angina pectoris, hypertension, pulmonary hypertension, heart failure and asthma. This by no means makes It obvious that these or similar compounds can be used as antiarrhythmics.

I
°'xxl"Xc:>
European patent application EP-A 0 947 500 claims a large, somewhat heterogeneous, quantity of compounds which are said to act as prostaglandin E2 antagonists or agonists. Most of the anthranilio acid derivatives present therein differ from the compounds of this application inter alia through the presence of a free carboxyl function.
European patent application EP-A 0 491 525 describes anthranilamides with various 5-membered heretocycles in the side chain, such as, for example, the compound F, and the use thereof for treating diabetes.

A potassium channel-blocking action Is not mentioned in any of these publications mentioned, so that the effect of the structurally related compounds of the formula I could not have been expected.
The present invention relates to compounds of the formula I,

R(9) is hydrogen or alky! having 1 or 2 carbon atoms;
R(10) is hydrogen or alkyl having 1 or 2 carbon atoms;
R(11) is cycloalkyi having 3, 4, 5 or 6 carbon atoms, phenyl,
where phenyl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, CF3,
OCF3, CN, COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms,
alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R{13) isCpH2p-R(14);
p isO, 1,2, 3 or 4;
R(14) is aryl or heteroaryl,
where aryl and heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl
having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R(2) is hydrogen; R(3) is alkyl having 3, 4 or 5 carbon atoms, phenyl,
where phenyl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, CF3, OCF3, COOMe,
CONH2, COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy
having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R(4), R(5), R(6) and R(7)
are, independently of one another, hydrogen, F, CI, CF3, OCF3, CN, COOMe,
CONH2, COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1,
2, 3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; and the pharmaceutical ly acceptable salts thereof.

Alkyl radicals and alkylene radicals may be straight-chain or branched. This also applies to the alkylene radicals of the formulae CnHgn- CmH2m 111 CpH2p. Alkyl radicals and alkylene radicals may also be straight-chain or branched if they are substituted or present in other radicals, e.g. in an alkoxy radical or in a fluorinated alkyl radical. Examples of alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3,3-dimethylbutyl, heptyl. The divalent radicals derived from these radicals, e.g. methylene, 1,1-ethylene, 1,2-ethylene, 1,1-propylene, 1,2-propylene, 2,2-propyiene, 1,3-propylene, 1,1-butylene, 1,4-butylene, 1,5-pentylene, 2,2-dimethyl-1.3-propylene, 1,6-hexylene etc., are examples of alkylene radicals.
CycloalkyI radicals may likewise be branched. Examples of cycloalkyi radicals having 3 to 7 carbon atoms are cyclopropyl, cyclobutyl, 1-methylcyclopropyl, 2-methyJcyclopropyl, cyclopentyl, 2-methylcyciobutyl. 3-methylcyclobutyl, cyclopentyl, cyclohexyl, 2-methylcyciohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cycloheptyl etc.
Heteroaryl radicals are, in particular, 2- or 3-thienyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4-or 5-imidazolyl, 1-, 3-, 4-or5-pyrazolyl, 1,2,3-triazol-1-,-4-or5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 1,2,3-oxadia20l-4- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-oxadiazol-2-yl or -5-yl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isofhiazo(y(, 1,3,4-fhiadiazo(-2- or -5-y(, 1,2,4-fhiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or 5-yl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 3- or 4-pyridazinyl, pyrazinyl, 1 -, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1 -, 2-, 4- or 5-benzimidazolyl, 1 -, 3-, 4-, 5-, 6- or 7-indazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-Isoquinolyi, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 3-, 5-, 6-, 7- or 8-quinoxalinyl, 1-, 4-, 5-, 6-, 7- or 8-phthalazinyl. The corresponding N-oxides of these compounds are also included, that is to say, for example, 1-oxy-2-, 3- or 4-pyridyl.
Particular preference is given to the heteroaromatic systems thienyl, furyl, pyrrolyl, imidazolyl, quinolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl.

Pyridyl means 2-, 3- and 4-pyridyl. Thienyl means both 2- and 3-thienyl. Furyl means both 2- and 3-fury(.
Aryl is phenyl and 2- or 3-naphthyl.
Monosubstituted phenyl radicals may be substituted in the 2, 3 or 4 position, disubstituted in the 2,3, 2,4, 2,5, 2,6, 3,4 or 3,5 positions, trisubstituted in the 2,3,4, 2,3,5, 2,3,6, 2,4,5, 2,4,6 or 3,4,5 positions. Corresponding statements also apply analogously to the N-containing heteroaromatic systems, the naphthyl, thiophene or furyl radical.
In the case of di- or trisubstitution of a radical, the substituents may be identical or different.
If the compounds of the formula I contain one or more acidic or basic groups or one or more basic heterocycles, the invention also includes the corresponding physiologically or toxicologically acceptable salts, in particular the pharmaceutically utilizable salts. Thus, the compounds of the formula I which have acidic groups, e.g. one or more COOH groups, can be used for example as alkali metal salts, preferably sodium or potassium salts, or as alkaline earth metal salts, e.g. calcium or magnesium salts, or as ammonium salts, e.g. as salts with ammonia or organic amines or amino acids. With compounds of the formula I in which R2 is hydrogen it is possible, for example, for the sulfonamide function to be deprotonated to form a sodium salt. Compounds of the formula I which have one or more basic, i.e. protonatable, groups or contain one or more basic heterocyclic rings can also be used in the form of their physiologically tolerated acid addition salts with inorganic or organic acids, for example as hydrochlorides, phosphates, sulfates, methanesulfonates, acetates, lactates, maleates, fumarates, malates, gluconates etc. If the compounds of the formula I contain t>oth acidic and basic groups in the molecule, the invention includes not onJy the salt forms described but also inner salts, called betaines. Salts can be obtained from the compounds of the formula I by conventional processes, for example by combining with an acid or base in a solvent or dispersant or else by anion exchange from other salts.

The compounds of the formula I may when appropriately substituted exist in stereoisomeric forms. If the compounds of the formula I contain one or more centers of asymmetry, these may have, independently of one another, the S configuration or the R configuration. The invention includes all possible stereoisomers, e.g. enantiomers or diastereomers, and mixtures of two or more stereoisomeric forms, e.g. enantiomers and/or diastereomers, in any ratios. The invention thus includes, for example, enantiomers in enantiopure form, both as levorotatory and as dextrorotatory antipodes, and in the form of mixtures of the two enantiomers in various ratios or in the form of racemates. Individual stereoisomers can be prepared if required by fractionating a mixture by conventional methods or, for example, by stereoselective synthesis. If mobile hydrogen atoms are present, all tautomeric forms of the compounds of the formula I are also encompassed by the present invention.
The compounds of the formula I can be prepared by various chemical processes, some examples of which are outlined as scheme 1 or 2 below. The radicals R(1) to R(7) used herein are In each case defined as indicated above.
As shown in scheme 1, compounds of the invention can be prepared, for example, by initially reacting an amino carboxylic acid of the formula II in a solvent such as water, pyridine or an ether in the presence of a base with a sulfonyl chloride of the formula R(3)-S02-CI or a sulfonic anhydride. Suitable as base are inorganic bases such as, for example, sodium carbonate or potassium hydroxide or organic bases such as, for example, pyridine or triethylamine.
The resulting sulfonylamino carboxylic acid of the formula III can then be activated, for example by reaction with a chlorinating agent such as, for example, phosphorus pentachloride, phosphorus oxychloride or thionyl chloride, in an inert solvent to give an acid chloride and then be reacted with an amine of the formula H-R1 to give the title compounds of the formula I. However, activation of the carboxyl group in the compound of the formula III can also take place in a different way, for example by one of the numerous methods familiar to the skilled worker and used in peptide chemistry

/
for forming amide bonds, for example by conversion into a mixed anhydride or an activated ester or with use of a carbodiimide such as dicyclohexylcarbodiimde.
The reaction of the activated sulfonylamino carboxylic acid with an amine of the formula H-R1 is advantageously carried out in an inert solvent such as, for example, pyridine, tetrahydrofuran or toluene without addition or with addition of an inert base, for example a tertiary amine or pyridine.

R7 ,S = 0 O" R3

R4 O
NH
R7 R2 -ei1ssR1

R4 O

R4 O

Scheme 1
Alternatively, as shown in scheme 2, it is also possible initially to react the anhydrides of the formula IV with an amine of the formula H-R1 to give an o-aminobenzamide of the formula VII, from which a compound of the formula I is then obtained by reaction with a sulfonyl chloride of the formula R(3)S02CI. Another possibility for preparing
intermediates of the formula VII in which R(2} is hydrogen comprises the amidation of an o-nitrobenzoic acid of the formula V with an amine of the formula HNR(1)R(2), followed by reduction of the nitro group to the amine.

/

N 1O
R4 0
R7,1Ba

H-R1

R1
M*'° H2. Pd
N H-R1 1 R6
R(3)S02Ct

R4 0
Scheme 2

R4 O
R7 O
VI

R4 0

It may be appropriate in all the procedures to protect functional groups in the molecule temporarily during certain reaction steps. Such protective group techniques are familiar to the skilled worl The compounds of the invention of the formula I and their physiologically tolerated salts can thus be used on animals, preferably on mammals and, in particular, on humans as pharmaceuticals on their own or in mixtures with one another or in the form of pharmaceutical preparations. The present invention also relates to compounds of the formula I and their physiologically tolerated salts for use as phamnaceuticals, to their use in the therapy and prophylaxis of the pathological states mentioned and to
their use for producing medicaments therefor and medicaments with K+ channel-blocking effect. The present invention further relates to pharmaceutical preparations which comprise as active ingredient an effective dose of at least one compound of the formula I and/or a physiologically tolerated salt thereof in addition to conventional

pharmaceutically acceptable carriers and excipients. The pharmaceutical preparations normally contain from 0.1 to 90% by weight of the compounds of the formula I and/or their physiologically tolerated salts. The pharmaceutical preparations can be produced in a manner known per se. For this purpose, the compounds of the formula I and/or their physiologically tolerated salts are converted together with one or more solid or liquid pharmaceutical carriers and/or excipients and, if desired, In combination with other active pharmaceutical ingredients into a suitable administration form or dosage form which can then be used as pharmaceutical in human medicine or veterinary medicine.
Pharmaceuticals which comprise compounds of the invention of the formula I and/or their physiologically tolerated salts can be administered orally, parenterally, e.g. intravenously, rectally, by inhalation or topically, the preferred administration depending on the individual case, e.g the particular manifestation of the disease to be treated.
The excipients suitable for the desired pharmaceutical formulation are familiar to the skilled worker on the basis of his expert knowledge. Besides solvents, gel formers, suppository bases, tablet excipients and other active ingredient carriers it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers, agents to achieve a depot effect, buffer substances or colorants.
The compounds of the formula I can also be combined with other active pharmaceutical ingredients to achieve an advantageous therapeutic effect. Thus, in the treatment of cardiovascular disorders, combinations with substances acting on the cardiovascular system are possible and advantageous. Such combination partners advantageous for cardiovascular disorders are, for example, other antiarrhythmics, i.e. class I, class II or class III antiarrhythmics, such as, for example, IKs- or IKp channel blockers, e.g. dofetilide, or, in addition, hypotensive substances such as ACE inhibitors (for example enalapril, captopril, ramipril), angiotensin antagonists, K+ channel activators, and alpha- and beta-receptor blockers, as well as sympathomimetic and

adrenergic compounds, and Na+/H+ exchange inhibitors, calcium channel blockers, phosphodiesterase inhibitors and other substances with a positive inotropic effect, such as, for example, digitalis glycosides, or diuretics.
For a form for oral use, the active compounds are mixed with the additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into the suitable administration forms such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily solutions. Examples of inert carriers which can be used are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. Preparation is possible in this connection both as dry and as wet granules. Suitable as oily carriers or as solvents are, for example, vegetable or animal oils, such as sunflower oil or fish liver oil. Examples of suitable solvents for aqueous or alcoholic solutions are water, ethanol or sugar solutions or mixtures thereof. Further examples of excipients, also for other administration forms, are polyethylene glycols and polypropylene glycols.
For subcutaneous or intravenous administration, the active compounds are converted into a solution, suspension or emulsion, if desired with the substar1ces customary for this purpose, such as solubilizers, emulsifiers or other excipients. The compounds of the formula I and their physiologically tolerated salts can also be lyophilized and the resulting lyophilizates be used for example to produce products for injection or infusion. Examples of suitable solvents are water, physiological saline or alcohols, e.g. ethanol, propanol, glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else mixtures of the various solvents mentioned.
Suitable as pharmaceutical formulation for administration In the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active ingredients of the formula I or of their physiologically tolerated salts in a pharmaceutically acceptable solvent such as, in particular, ethanol or water, or a mixture of such solvents. The formulation can if required also contain other pharmaceutical excipients such as surfactants, emulsifiers and stabilizers, and a propeliant gas. Such a

preparation normally contains the active ingredient in a concentration of about 0.1 to 10, in particular of about 0.3 to 3, percent by weight.
The dosage of the active ingredient of the formula I to be administered or of the physiologically tolerated salt thereof depends on the individual case and should be adapted in a conventional way to the circumstances of the individual case for an optimal effect. Thus, of course, it depends on the frequency of administration and on the potency and duration of action of the compounds employed in each case for therapy or prophylaxis, but also on the nature and severity of the disease to be treated and on the sex, age, weight and individual response of the human or animal to be treated and on whether the therapy is acute or prophylactic. The daily dose of a compound of the formula I is normally, on administration to a patient weighing about 75 kg, from 0.001 mg/kg of bodyweight to 100 mg/kg of bodyweight, preferably 0.01 mg/kg of bodyweight to 20 mg/kg of bodyweight. The dose can be administered in the form of a single dose or else be divided into a plurality of, e.g. two, three or four single doses. Especially in the treatment of acute cases of cardiac arrhythmias, for example on an intensive care ward, parenteral administration by injection or Infusion, e.g. by a continuous intravenous infusion, may also be advantageous.

Experimental part
List of abbreviations
DMAP 4-dimethylaminopyridine
DMF N,N-dimethylformamide
EDAC N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride
EA ethyl acetate
HOBT 1-hydroxy-1H-benzotriazole
RT room temperature
THF tetrahydrofuran
BuLi butyllithium
General method 1: Reaction of anthranilic acids with sulfonyl chlorides to give o-sulfonylaminobenzoic acids (analogous to Organic Syntheses 1952, 32, 8)
1.2 mol of the appropriate sulfonyl chloride are added in portions at 60°C to a solution of 260 g (2.4 mol) of sodium carbonate and 1 mol of the appropriate anthranilic acid in 1.5 I of water. The reaction mixture is heated at 60-80°C until the reaction is complete (about 1-6 h), adding further sulfonyl chloride if necessary. After cooling, the reaction mixture is poured into 500 ml of 6 molar hydrochloric acid, and the precipitate is filtered off with suction and dried in vacuo in an oven at 45°C. If the product does not result as crystals, it is isolated by extraction with ethyl acetate.

Precursor 1 a: 2-(Toluene-4-sulfonylamino)benzoic acid

9.6 g of the title compound were obtained as a white solid from 6.85 g of anthranilic acid and 10.5 g of para-toluenesulfonyl chloride by general method 1. MS{ES):293(M+1).
Precursor 1 b: 2-Butylsulfonylamino-5-methylbenzoic acid

4.2 g of 2-butylsulfonylamino-5-methylbenzoic acid were obtained from 5 g of 5-methylanthranilic acid and 6.2 g of butanesulfonyl chloride by general method 1. MS(ES):272(M+1).
Precursor 1 c: 2-{4-Methoxybenzenesulfonylamino)-6-methylbenzoic acid

/
Precursor 2 a: 2-(4-Toluenesulfonylamino)benzoyl chloride

7.5 g of the title compound were isolated as white solid from 9.6 g of 2-(toluene-4-sulfonylamino)benzoic acid (precursor 1 a) and 8.3 g of phosphorus pentachloride. IVIS (ES, detected as methyl ester after addition of methanol): 306 (l\1+1).
B) with thionyl chloride
8 mmol of the sulfonylaminobenzoic acid are heated in 6 ml of thionyl chloride at 60°C
for 3 h, and concentrated, and the residue is coevaporated twice with toluene.
Precursor 2 b: 2-(4-Methoxybenzenesulfonylamino)benzoyl chloride

NH I 0=S
a
1CI
"1

o

2.2 g of the title compound were obtained from 2.4 g of 2-(4-methoxybenzenG-
sulfonylamino)benzoic acid and 5 ml of thionyl chloride.
MS (ES, detected as methyl ester after addition of methanol): 322 (M+1).

acetic acid, stirred at room temperature for 6 h. The solution is concentrated, taken up in ethyl acetate and washed twice with NaHCOs solution. The organic phase is
concentrated, and the residue is distilled under high vacuum. In the case of involatile secondary amines, volatile constituents are distilled off and the residue is dissolved in ether/THF and, after addition of ethereal HCI solution, the precipitated hydrochloride is filtered off with suction, washed with ether and dried. The prepared secondary amines were employed without further purification for the reactions with the sulfonylaminobenzoyi chlorides or sulfonylaminobenzoic acids.
Precursor 3 a: Benzyl(1-methyl-1 H-imidazol-2-ylmethyi)amine

The hydrochloride (20.5 g) was prepared from 19.4 g of benzylamine and 10 g of 2-formyl-1-methylimida2ole by the general procedure. MS(ES+):m/z = 202(M+1).
Precursor 3 b: Benzylpyrldin-3-ylmethylamine

The secondary amine (2.8 g) was prepared by the general procedure from 4.32 g of 3-pyridylmethylamine and 2.12 g of benzaldehyde after Kugelrohr distillation under 0.1 mbarat 130°C.
MS(ES+):m/z=199(M+1).

General method 3 B: Preparation of a-branched annines from ketones
A solution of 67 mmol of the appropriate ketone in 120 ml of ethanol is added dropwise to a solution of 200 mmol of hydroxylammonium chloride and 200 ml of sodium acetate in 120 ml of water at 30°C, and the mixture is heated at SO'C until reaction is complete {1-3 h). After cooling, the reaction mixture is diluted with water, and the precipitated oxide is filtered off with suction or, if necessary, isolated by extraction. The resulting product is dissolved in 100 ml of methanol, 100 ml of THF and 10 ml of concentrated ammonia solution and hydogenated in the presence of Raney nickel at RT under atmospheric pressure until hydrogen uptake ceases. Removal of the catalyst by filtration and concentration of the reaction mixture results in the corresponding amine which is purified by chromatography if necessary.
Precursor 3 1:1-Benzylpropylamine

4.5 g of the title compound were obtained from 10 g of 1-phenyI-2-butanone by general method 3.
Precursors m; 1-Pyridin-4-ylpropyIamine

N\1
10.2 g of the title compound were obtained from 10 g of 4-propionylpyridine by general method 3 B.
Precursor 3 n : 1-Pyridin-3-yl-propylamine

0.9 g of the title compound was obtained from 1 g of 4-propionylpyridine by general method 3 B.
Precursors s: 1-Cyclopropyl-1-phenylmethylamine hydrochloride

H1N

a) N-(Cyclopropylphenylmethyl)formamide

14.8 g (0.1 mol) of cyclopropyi phenyl ketone, 11.4 ml (0.3 mol) of formic acid and 20 ml (0.5 mol) of formamide were heated at 160°C for 18 h. After cooling, 10O ml of water were added and the mixture was extracted 2x with 50 ml of ether each tinrie. The ethereal phase was washed with 50 ml of 10 % Na2C03 solution, dried over Na2S04 and concentrated. 13.6 g (77.4 mmol) of a yellow oil were obtained.
b) 1-Cyclopropyl-1-phenylmethylamine hydrochloride
13.6 g (77.4 mmol) of N-(cyclopropylphenylmethyl)formamide (see a) were heated to reflux in 100 ml of 2N HCl for 18 h. After cooling, the mixture was extracted 2x with 50 ml of dichloromethane each time, and the aqueous phase was concentrated. The residue was taken up in 30 ml of 2-propanol, heated to boiling and cooled in a refrigerator overnight. The crystals of 1 -cyclopropyi-1 -phenylmethylamine hydrochloride which had separated out (3.85 g, 21 mmol) were filtered off with suction and dried in a vacuum oven.
Precursor 31: Cyclopropylpyridin-2-yl-methylamine hydrochloride

a)Cyclopropylpyridin-2-ylmethyleneamlne
25 g (157.5 mmol) of 2-bromopyridlne in 100 ml of diethyl ether were added dropwise over the course of 20 min to 100 ml (160 mmol) of n-BuLi solution in 300 ml of diethyl ether at -70°C. The dark red solution was stirred for 5 h and then 8.8 g (131 mmol) of cyclopropanecarbonitrile in 100 m! of ether were added. The mixture was stirred at -70'C for 30 min, warmed to room temperature and stirred for a further 30 min. Then 15 g of Na2S04 x 10 H2O were added, and stirring was continued for 1 h. The red solution was mixed with Na2S04, filtered and concentrated. The product was distilled

in a Kugelrchr apparatus at 75°C-120°C/0.3mbar as a pale yellow oil (18.6 g, 127 mmol) and was stored at -IS1C.
b) Cyclopropylpyridin-2-ylm6thylan\in6 hydrochloride
2.72 g (18.6 mmol) of cyclopropylpyridin-2-ylmethyleneamine (see a) were dissolved in 35 ml of dry methanol. At 0°C, 0.69 g (18.6 mmol) of NaBH4 was added in portions.
After 30 min at 0°C, the mixture was stirred at room temperature for 2 h and, after adjustment to pH 3 with 1M HCI, the methanol was stripped off in a rotary evaporator and the residue was freeze-dried. 8.8 g of cyclop ropylpyridin-2-ylmethy la mine hydrochloride mixed with inorganic salts and boric acid were obtained.
Precursor 3 u: Cyclopropylpyridin-3-ylmethylamine hydrochloride

a) Cyclopropylpyridin-3-ylmethyleneamine
7.5 g (51 mmol) of the imine were isolated as a yellow oil in accordance with the method for precursor 3 p starting from 8.8 g (131 mmol) of cyclopropanecarbonitrile, 25 g (157.5 mmol) of 3-bromopyridine and 173 mmol of n-BuLi solution and after Kugelrohr distillation (130°C/0.2mbar).
b) Cyclopropylpyridin-3-ylmethylamine hydrochloride
16.6 g of cyclopropylpyridin-3-yln:iethylamine hydrochloride mixed with inorganic salts and boric acid were obtained in accordance with the method for precursor 3 p starting from 7.5 g (51.5 mmol) of imine (see a) and 1.9 g (51.4 mmol) of NaBH4.

Precursor 3 v: 1-(5-Methylfuran-2-yl)propylamine
"■1
11.35 g (180 mmol) of sodium cyanoborohydride were introduced in portions into 5 g (36 mmol) of 2-metbyl-5-propionylfuran and 28.2 g (366 mmol) of ammonium acetate in 300 ml of methanol with stirring and left to react at RT for 18 h. The mixture was substantially concentrated and, after addition of 200 ml of dichloromethane, the organic phase was washed 3x with 50 ml of NaHCOs solution each time, dried over
Na2S04 and concentrated. 3.9 g (28 mmol) of the amine were obtained in the fonn of
a pale yellow oil.
Precursor 3 w: 1-Phenylprop-2-ynylamine hydrochloride

H1N'

The compound was prepared in accordance with the method of Bjom M. Nilsson et al., J. Heterocycl. Chem. (1989), 26(2), 269-75 starting from 1-phenyl-2-propynyl alcohol by a Rltter reaction and subsequent hydrolysis with hydrochloric acid.
Precursor 3 x: C-Cyclopropyl-C-(6-methoxypyridin-2-yl)methylamine

N1O1

a) Cyclop ropanecarbaldehyde 0-benzyloxime
6.7 g {95.6 mmoi) of cyclopropanecarbaldehyde were stirred together with 15.3 g
(95.6 mmol) of 0-benzylhydroxylamine and 15.7 g (191.2 mmol) of sodium acetate in
250 ml of ethanol at room temperature for 18 h and, after concentration, Na2S04 was
added. The residue was extracted 3x with 50 ml of dichloromethane each time, the organic phase was concentrated, and the crude product was purified by chromatography on silica gel. 5 g (28.6 mmol) of a colorless liquid were obtained.
b) 0-Benzyl-N-[cyclopropyl-(6-methoxypyridin-2-yl)methyl]hydroxyiamine
8.8 ml (22 mmol) of n-BuLi (2.5 M in toluene) were added to 3.76 g (20 mmol) of
2-bromo-6-methoxypyridine in 20 ml of THF at -TSX. After 30 min, this dark red
solution was added to a solution of 1.4 g {8 mmol) of cyclopropanecarbaldehyde
0-benzyloxime (see a) and 2.52 ml (20 mmol) of BF3 etherate in 40 ml of toluene
which had been stirred at -78°C for 15 min. The mixture was stirred at -78°C for 4 h, slowly warmed to RT and, after addition of water, made alkaline with saturated Na2C03 solution.
The organic phase was separated off, the aqueous phase was extracted with toluene, and the combined organic phases were dried over Na2S04 and concentrated. The crude product was taken up in 12 ml of acetonltrlle, insolubles were removed, and the product was isolated by preparative HPLC (650 mg, red oil).
c) C-Cyclopropyl-C-(6-methoxypyridin-2-yl)methylamine
650 mg (2.3 mmol) of 0-bGnzyl-N-[cyclopropyl-(6-methoxypyridin-2-yl)methyl]-hydroxylamine (see b) were dissolved in 18 ml of glacial acetic acid and diluted with

/
18 ml of water. 3.3 g of zinc dust were added, and the suspension was reacted in an ultrasonic bath for 24 h. The mixture was filtered through kieselguhr, washed with 50% acetic acid, and the filtrate was partially evaporated and adjusted to pH 11 with saturated NagCOs solution. It was extracted 3x with 100 ml of dichloromethane each
time, dried over Na2S04 and concentrated. 0.4 g (2.2 mmol) of the product was
obtained in the form of a dark red oil.
General method 4 A: Preparation of 2-aminobenzamides from 2-nitrobenzoic acids
The appropriate 2-nitrobenzoic acid is initially reacted in analogy to general methods 2 and 5 with the respective amine to give a 2-nitrobenzamide. Then 4 mmol of the 2-nitrobenzamlde are hydrogenated in 50 ml of THF and 50 ml of methanol in the presence of a spatula tip of 10% palladium on carbon at RT under atmospheric pressure. The catalyst is filtered off with suction, the reaction mixture is concentrated, and the corresponding 2-aminobenzamtde is obtained.
The following precursor was, inter alia, synthesized in this way:

Precursor Structure Mass
4a "9
(V"" 318 (M+1)
General method 4 B; Preparation of 2-aminobenzamides from isatoic anhydride
A solution of 20 mmol of isatoic anhydride and 22 mmol of the appropriate amine in 75 ml of DMF is heated at 60°C until reaction is complete. 100 ml of water are added to the reaction mixture, and the product is filtered off with suction or isolated by extraction.

Precursor 4 b; (S)-2-Amino-N-{1-phenylpropyl)benzamide

3.4 g of the title compound were obtained from 3 g of (S)-l-phenylpropylamine and 3.2 g of Isatoic anhydride after 2 h at 60°C in accordance with general method 4 b.
General method 5: Reaction of sulfonylaminobenzoyl chlorides with amines
0.6 mmol of the particular sulfonylaminobenzoyl chloride is added to a solution of 0.66 mmol of the particular amine and 0.9 mmol of triethylamine in 3 ml of methylene chloride, and the mixture is stirred at room temperature overnight. The reaction mixture is diluted with 5 ml of water and 10 ml of methylene chloride, and the organic phase is washed successively with 1M hydrochloric acid solution and saturated sodium bicarbonate solution. After drying over magnesium sulfate, the solution is concentrated in vacuo, and the product is purified as necessary by preparative HPLC or column chromatography.
Example 1: (S)-2-Phenylsulfonylamino-5-chloro-N-(1-phenylethyl)benzamide

Example 6: (R)-2-Phenylsulfonylamino-5-chloro-N-[1 -(4-melhoxyphenylethyl]-benzamide
Xn1.

0=3=0

112 mg of the title compound were obtained from 2-phenylsulfonylamino-5-chloro-benzoyl chloride artd R-(+)-1-(4-methoxyphenyl)ethylamine in accordance with general method 5. MS (ES+): m/z = 445 {M+1).
Example 7: 2-Phenylsulfonylamino-5-chloro-N-(phenylpyridin-2-ylmethyl)benzamide

211 mg of the title compound were obtained from 2-phenylsulfonylamino-5-chlorobenzoyl chloride and C-phenyl-C-pyridin-2-ylm0thylamine in accordance with general method 5. MS (ES+): m/z = 478 (M+1).

mixture is diluted with EA and washed with dilute hydrochloric acid and sodium bicarbonate solution. Drying over magnesium sulfate and concentrating in vacuo result in the appropriate amide which is purified if necessary by preparative HPLC
Beispiel54:2-(Butylsulfonylamino)-N-cyclohexyl-5-methylbenzamide

184 mg of the title compound were obtained from 200 mg of 2-butylsulfonylamino-5-methylbenzoic acid (precursor 1 b) and cyclohexylamine in accordance with general method 6. MS (ES+): m/z = 353 (M+1).

General method 7: Reaction of 2-aminobenzamides with sulfonyl chlorides A solution of 0.3 mmol of the appropriate sulfonyl chloride in 2 ml of methylene chloride is added dropwise to a solution of 0.2 mmol of the appropriate 2-aminobenzam)de (precursor 4) and 0.6 mmol of pyridine in 5 ml of methylene chloride at 0°C, and the mixture is stirred at RT overnight. The organic phase is washed with water, dilute hydrochloric acid and sodium bicarbonate solution, and the resulting crude product is purified If necessary by preparative HPLC.

The 3-methylbutylsulfonyl chloride required for example 74 was prepared from 3-methylbutyl bromide by reaction with ammonium sulfite solution under reflux to give the sulfonic acid, followed by chlorination with phosphorus pentachloride to give the B sulfonyl chloride.
The following compounds were additionally obtained in analogy to the above examples and by use of one or more of general methods 1-7:

The following further examples were prepared in accordance with general method 5:

The compound was obtained from the compound of example 90 by cleavage of the methyl ether with boron tribromide.
Pharmacological investigations
Human Kvl .5 channels were expressed in xenopus oocytes. For this purpose, firstly oocytes were isolated from Xenopus laevis and were defolliculated. Kvl .5-encoding RNA which had been synthesized in vitro was then injected into these oocytes. After 1-7 days of Kvl .5 protein expression, the Kvl .5 currents were measured on the oocytes by the two-microelectrode voltage clamp technique. The Kv1.5 channels were for this purpose usually activated with voltage jumps lasting 500 ms to 0 mV and 40 mV. A solution of the following composition flowed through the bath: NaCl 96 ivU, KCI 2 mM, CaCl2 1.8 mM, MgClg 1 mM, HEPES 5 mM (titrated to pH 7.4 with NaOH). These experiments were carried out at room temperature. The following were employed for data acquisition and analysis: geneclamp amplifier (Axon Instruments, Foster City, USA) and MacLab D/A converter and software (ADInstruments, Castle Hill, Australia). The substances of tfie invention were tested by adding them in various concentrations to the bath solution. The effects of the substances were calculated as percentage inhibition of the Kvl .5 control current which was obtained when no substance was added to the solution. The data were then extrapolated using the Hill equation in order to determine the inhibitory concentrations IC50 for the respective
substances.
The following IC50 values were determined in this way for the compounds listed below:

mixture is diluted with EA and washed with dilute hydrochloric acid and sodium bicarbonate solution. Drying over magnesium sulfate and concentrating in vacuo result in the appropriate amide which is purified if necessary by preparative HPLC
Beispiel54:2-(Butylsulfonylamino)-N-cyclohexyl-5-methylbenzamide

184 mg of the title compound were obtained from 200 mg of 2-butylsulfonylamino-5-methylbenzoic acid (precursor 1 b) and cyclohexylamine in accordance with general method 6. MS (ES+): m/z = 353 (M+1).

General method 7: Reaction of 2-aminobenzamides with sulfonyl chlorides A solution of 0.3 mmol of the appropriate sulfonyl chloride in 2 ml of methylene chloride is added dropwise to a solution of 0.2 mmol of the appropriate 2-aminobenzam)de (precursor 4) and 0.6 mmol of pyridine in 5 ml of methylene chloride at 0°C, and the mixture is stirred at RT overnight. The organic phase is washed with water, dilute hydrochloric acid and sodium bicarbonate solution, and the resulting crude product is purified If necessary by preparative HPLC.

The 3-methylbutylsulfonyl chloride required for example 74 was prepared from 3-methylbutyl bromide by reaction with ammonium sulfite solution under reflux to give the sulfonic acid, followed by chlorination with phosphorus pentachloride to give the B sulfonyl chloride.
The following compounds were additionally obtained in analogy to the above examples and by use of one or more of general methods 1-7:

The following further examples were prepared in accordance with general method 5:

The compound was obtained from the compound of example 90 by cleavage of the methyl ether with boron tribromide.
Pharmacological investigations
Human Kvl .5 channels were expressed in xenopus oocytes. For this purpose, firstly oocytes were isolated from Xenopus laevis and were defolliculated. Kvl .5-encoding RNA which had been synthesized in vitro was then injected into these oocytes. After 1-7 days of Kvl .5 protein expression, the Kvl .5 currents were measured on the oocytes by the two-microelectrode voltage clamp technique. The Kv1.5 channels were for this purpose usually activated with voltage jumps lasting 500 ms to 0 mV and 40 mV. A solution of the following composition flowed through the bath: NaCl 96 ivU, KCI 2 mM, CaCl2 1.8 mM, MgClg 1 mM, HEPES 5 mM (titrated to pH 7.4 with NaOH). These experiments were carried out at room temperature. The following were employed for data acquisition and analysis: geneclamp amplifier (Axon Instruments, Foster City, USA) and MacLab D/A converter and software (ADInstruments, Castle Hill, Australia). The substances of tfie invention were tested by adding them in various concentrations to the bath solution. The effects of the substances were calculated as percentage inhibition of the Kvl .5 control current which was obtained when no substance was added to the solution. The data were then extrapolated using the Hill equation in order to determine the inhibitory concentrations IC50 for the respective
substances.
The following IC50 values were determined in this way for the compounds listed below:

WE CALIM:
1. A compound of the formula I,

A is -CnH2n-;
n isO 1,2, 3, 4 or 5;
O is oxygen;
D is a bond or oxygen;
E is -CmH2m-;
m isO, 1,2,3,4 or 5;
R(8) is hydrogen, alkyl having 1,2, 3 or 4 carbon atoms or CpH2p-R{14);
p isO, 1,2,3.4or5;
R(14) is cycloalkyl having 3, 4, 5 or 6 carbon atoms, aryl or
heteroaryl, where aryl and heteroaryl are unsubstituted or substituted by 1,2 or 3 substituents selected from the group consisting of F, CI, Br, I, CF3, OCF3, NO2. CN, COOMe,
CONH2, COMe, NH2. OH, alkyl having 1. 2,3 or 4 carbon atoms, alkoxy having 1,2,3 or 4 cartjon atoms, dimethyl-amino, sutfamoyi, methylsultonyl and methylsulfonylamino;

R(9) is hydrogen or alkyl having 1, 2,3,4, 5 or 6 carbon atoms;
R(10) is hydrogen, alkyl hawng 1,2, 3 or 4 carbon atoms, cycloalkyi having 3, 4, 5 or 6 carbon atoms, aryl or heteroaryl,
where aryl and heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, Br, I, CF3. OCF3, NO2, CN, COOMe, CONH2, COMe,
NH2, OH, alkyl having 1, 2, 3 or 4 carbon atoms, aikoxy having
1, 2, 3 or 4 cart>on atoms, dimethylamino, methylsulfonyl and methylsulfonylamino;
R(11) is cycloalkyi having 3.4, 5 or 6 carbon atoms, phenyl, naphthyt, thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl or pyrimidyl,
where phenyl, naphthyl, thienyl. furyl, pyridyl, pyrazinyl, pyridcizinyl and pyrimidyl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, Br, I, CF3, OCF3, NO2, CN, COMe. NHg, OH, alkyl having 1,
2. 3 or 4 carbon atoms, aikoxy having 1, 2, 3 or 4 cartJon
atoms, dimethylamino. sulfamoyi. methylsulfonyl and
m ethylsulf onyfamino;
R(12) is alkyl having 1,2,3 or 4 carbon atoms, cycloalkyi having 3,4,5 or 6 carbon atoms, aryl or heteroaryl,
where aryl and heteroaryl are unsubstituted or substituted by 1,2 or 3 substituents selected from the group consisting of F. CI, Br, I, CF3, OCF3, NO2. CN, COOMe, C0rMH2, COMe, NH2, OH, alkyl having 1,2,3 or 4 carbon atoms, aikoxy having 1. 2, 3 or 4 carbon atoms, dimethylamino. sulfamoyi, methylsulfonyl and methylsulfonylamino;
R(13) isCpH2p-R(14);
p is 0, 1,2, 3, 4 or 5;
R(14) is cycloalkyi having 3.4, 5 or 6 carbon atoms
tetrahydrofuranyl, tetrahydropyranyl, aryl or heteroaryl.

where aryl and heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI, Br, I, CF3, OCF3, NO2. CN, COOMe, CONH2. COMe. NH2, OH, alkyl having 1, 2,3 or 4 carbon atoms, alkoxy having
1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R(15) is cycloalkyi having 3,4. 5, 6, 7 or 8 carbon atoms; R(2) is hydrogen or alkyl having 1,2, 3 or 4 carbon atoms; R(3) is alky! having 3, 4,5, 6 or 7 carbon atoms, cycloalkyi having 3, 4, 5 or 6 carbon atoms, phenyl or naphthyl,
where phenyl or naphthyl are unsubstituted of substituted by 1,2 or 3 substituents selected from the group consisting of F, CI, Br, I, CF3,
OCF3. NO2, CN, COOMe, C0f1H2, COMe. NH2, OH. alkyl having 1, 2. 3 or 4 carbon atoms, alkoxy having 1, 2,3 or 4 carbon atoms, dimethylamino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R(4), R(5), R(6) and R(7)
are. independently of one another, hydrogen, F, CI. Br, I, CF3. OCF3. OCHF2, NO2. CN. COOMe, CONH2, COMe. NH2, OH, alkyl having 1. 2, 3 or 4 carbon atoms, alkoxy having 1, 2,3 or 4 cartxan atoms, dimethylamino. sutfeimoyl. methylsulfonyl and methylsulfonylamino; and the phannaceutically acceptable salts thereof.
2- The compound of the formula I as claimed in claim 1, in which: R(1)is
"1NXA'°1E'-1 "1.X.'11E--1 ."\V;VE'-1
A is -CnH2n-;
n isO, 1, 2.3,4 or 5;
O is oxygen;

D is a bond or oxygen;
E is -CmH2m-i
m isO, 1,2, 3, 4 or 5;
R(8) is hydrogen, alkyl having 1,2, 3 or4 carbon atoms or CpH2p-R(14):
p ISO, 1,2, 3, 4 or 5;
R(14) is cycloalkyi having 3, 4, 5 or 6 carbon atoms, aryl or
hetefoaryl. where aryl and heteroaiyl are unsubstiluted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI. Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2. OH, alkyl having 1. 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethyl-amino, sulfamoyi, methylsulfonyl and methylsulfonylamino; R(9) is hydrogen or alkyl having 1, 2. 3, 4,5 or 6 carbon atoms; R(10) is hydrogen, alkyl having 1. 2, 3 or4 carbon atoms, cycloalkyi having 3, 4. 5 or 6 carbon atoms, aryl or heteroaryl,
where aryl and heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, CI. Br, I. CF3, OCF3, NO2. CN, COOMe. CONH2. COMe. NH2, OH, alkyl having 1. 2. 3 or 4 cart)on atoms, alkoxy having
1, 2.3 or 4 carbon atoms, dimethylamino, sulfamoyi.
methylsulfonyl and methylsulfonylamino;
R(11) is cycloalkyi having 3,4, 5 or 6 carbon atoms, phenyl or pyridyl,
where phenyl and pyridyl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F. CI, Br. I. CF3, OCF3. NO2. CN, COMe, NH2, OH, alkyl having 1,
2, 3 or 4 carbon atoms, alkoxy having 1, 2,3 or 4 carbon
atoms, dimethylamino, sulfamoyi, methylsulfonyl and
methy Isu If onylamino;
R(12) is alkyl having 1, 2.3 or 4 carbon atoms, cycloalkyi having 3, 4,5 or 6 carbon atoms, aryl or heteroaryl.

having 1, 2, 3 or 4 carbon atoms, drnnethylamino, sulfamoyt,
methylsulfonyl and methyisulfonylamino; R{4), R(5), R(6) and R(7)
are, independently of one another, hydrogen, F, CI, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, aikoxy having 1,
2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl. methylsulfonyl and methyisulfonylamino; and the phanmaceutically acceptable salts thereof.

9. A pharmaceutical preparation comprising an effectiveamountof at least one compound of the formula I as claimed in one or more of claims 1 to 6 and/or of a physiologically tolerated salt thereof as a active ingredient together with pharmaceutically acceptable carriers and additives and, where appropriate, also or more other pharmacological active ingredients.

Documents:

1696-chenp-2003 abstract.pdf

1696-chenp-2003 claims-duplicate.pdf

1696-chenp-2003 claims.pdf

1696-chenp-2003 correspondence-others.pdf

1696-chenp-2003 correspondence-po.pdf

1696-chenp-2003 description (complete)-1.pdf

1696-chenp-2003 description (complete)-2.pdf

1696-chenp-2003 description (complete)-duplicate.pdf

1696-chenp-2003 form-1.pdf

1696-chenp-2003 form-13.pdf

1696-chenp-2003 form-18.pdf

1696-chenp-2003 form-26.pdf

1696-chenp-2003 form-3.pdf

1696-chenp-2003 form-5.pdf

1696-chenp-2003 pct.pdf

1696-chenp-2003 petition.pdf

« Previous Patent

Next Patent »

Patent Number

224331

Indian Patent Application Number

1696/CHENP/2003

PG Journal Number

49/2008

Publication Date

05-Dec-2008

Grant Date

10-Oct-2008

Date of Filing

27-Oct-2003

Name of Patentee

SANOFI-AVENTIS DEUTSCHLAND GmbH

Applicant Address

BRUNINGSTRASSE 50, D-65929 FRANKFURT AM MAIN,

Inventors:

#	Inventor's Name	Inventor's Address
1	PIRARD, BERNARD	ECKENHEIMER LANDSTRASSE 39, 60318 FRANKFUT,
2	PEUKERT, STEFAN	HEILIGKREUZGASSE 9A, 60313 FRANKFURT,
3	KLEEMANN, HEINZ-WERNER	MAINSTRASSE 29, 65474 BISCHOFSHEIM,
4	BRENDEL, JOACHIM	LANDGRABENSTRASSE 23, 61118 BAD VILBEL,
5	HEMMERLE, HORST	8681 JAFFA COURT E. DRIVE, APT. #22, INDIANAPOLIS, IN 46240,

PCT International Classification Number

A61K31/18

PCT International Application Number

PCT/EP02/04138

PCT International Filing date

2002-04-13

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	10121003.5	2001-04-28	Germany